Julia L. Glade Bender, MD

Interim Division Director

Academic Title(s)

  • Associate Professor of Pediatrics at CUMC

Education & Training

  • Internship
    Mount Sinai Medical Center
  • Residency
    Mount Sinai Medical Center
  • Fellowship
    Memorial Sloan-Kettering Cancer Center, NY
  • Medical School
    University of Pennsylvania School of Medicine

Interests/Specialties

  • Developmental Therapeutics
  • Immunotherapy
  • Molecular Medicine
  • Pediatric Hematology-Oncology
  • Pediatrics

Conditions

Research & Grants

Go to Publications

Faculty Statement

I am a pediatric oncologist who specializes in the treatment of difficult solid tumors including neuroblastoma and sarcoma. I have close ties to the laboratory; however, my research occurs by the bedside and in the clinic, with the goal of bringing the newest drugs and diagnostic technologies to children with high risk, hard to treat, or resistant cancers. I direct the Pediatric Cancer Foundation Developmental Therapeutics Program. In this role, I provide the primary clinical oversight for over 30 trials of novel anti-cancer agents including first-in-children, phase 1 and 2 studies for relapsed and refractory leukemia, brain and other solid tumors. I currently serve as the Medical Director for the Precision in Pediatric Cancer through sequencing or “PIPseq” initiative at CUMC.

In collaboration with Dr. Darrell Yamashiro we developed anti-angiogenic agents, or drugs which stem the growth of tumor associated blood vessels by blocking the most critical vessel related factor, vascular endothelial growth factor (VEGF). We took these agents from the bench into national clinical trials of bevacizumab (AvastinTM) and aflibercept, and later, several multi-tyrosine kinase inhibitors including sorafenib, sunitinib, and pazopanib. We have developed several concepts currently in the pipeline for trials of drugs and drug combinations which exploit numerous novel mechanisms including agents which block the release of activating proteins, as well as drugs which help retain tumor suppressor protein function, and small molecule inhibitors of various growth pathways.

On a national level, I have provided scientific leadership for over 15 early phase clinical trials sponsored by the National Cancer Institute (NCI), the Children’s Oncology Group (COG), and pharmaceutical industry. I serve on numerous prominent COG committees including the Steering Committees for Developmental Therapeutics (DVL), Bioethics, Bone Tumors, and Neuroblastoma. I serve as the leader of the task force on post-consolidation “maintenance” therapies and immunotherapy strategies for neuroblastoma as well as the developmental therapeutics liaison for both the neuroblastoma and bone tumor committees. I serve as the vice chair of COG protocol AEWS1221 that is studying whether blocking the insulin like growth factor receptor (IGF-R1) in combination with chemotherapy produces better disease control than chemotherapy alone.

I am a consultant to the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) and have recently been appointed as a member of the NCI Pediatric and Adolescent Solid Tumor Steering Committee (PASTSC), one of 17 NCI steering committees that critically evaluate concepts for new trials from across the NCI-supported clinical trials enterprises and international partners.

+ Read More